Clinical Outcomes of Escalation vs Early Intensive Disease-Modifying Therapy in Patients With Multiple Sclerosis-Reference-Cited by-同舟云学术

Clinical Outcomes of Escalation vs Early Intensive Disease-Modifying Therapy in Patients With Multiple Sclerosis

Published:2019-05-01 Issue:5 Volume:76 Page:536
ISSN:2168-6149
Container-title:JAMA Neurology
language:en
Short-container-title:JAMA Neurol

Author:

Harding Katharine¹²³,Williams Owain¹²,Willis Mark¹²,Hrastelj James¹²,Rimmer Anthony³,Joseph Fady³,Tomassini Valentina¹²,Wardle Mark²,Pickersgill Trevor²,Robertson Neil¹²,Tallantyre Emma¹²

Affiliation:

1. Institute of Psychological Medicine and Clinical Neuroscience, School of Medicine, Cardiff University, Heath Park, Cardiff, United Kingdom

2. Helen Durham Centre for Neuroinflammatory Disease, University Hospital of Wales, Heath Park, Cardiff, United Kingdom

3. Department of Neurology, Royal Gwent Hospital, Newport, United Kingdom

Publisher

American Medical Association (AMA)

Subject

Neurology (clinical)

Link

http:///jamaneurology/article-pdf/76/5/536/17579728/jamaneurology_harding_2019_oi_180112.pdf

Reference27 articles.

1. Association between use of interferon beta and progression of disability in patients with relapsing-remitting multiple sclerosis.;Shirani;JAMA,2012

2. Effectiveness and cost-effectiveness of interferon beta and glatiramer acetate in the UK Multiple Sclerosis Risk Sharing Scheme at 6 years: a clinical cohort study with natural history comparator.;Palace;Lancet Neurol,2015

3. Modelling disease progression in relapsing-remitting onset multiple sclerosis using multilevel models applied to longitudinal data from two natural history cohorts and one treated cohort.;Tilling;Health Technol Assess,2016

4. Long-term evolution of multiple sclerosis disability in the treatment era.;Cree;Ann Neurol,2016

5. Interferon beta use and disability prevention in relapsing-remitting multiple sclerosis.;Greenberg;JAMA Neurol,2013

Cited by 195 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Highly Effective Therapy Versus Escalation Approaches in Early Multiple Sclerosis;Neurologic Clinics;2024-02

2. The T1-dark-rim: A novel imaging sign for detecting smoldering inflammation in multiple sclerosis;European Journal of Radiology;2024-02

3. Use of multiple sclerosis disease-modifying therapies during pregnancy in France: Nationwide study between 2010 and 2021;Multiple Sclerosis Journal;2024-01-27

4. Personalized Use of Disease-Modifying Therapies in Multiple Sclerosis;Pharmaceutics;2024-01-17

5. Insights for Healthcare Providers on Shared Decision-Making in Multiple Sclerosis: A Narrative Review;Neurology and Therapy;2024-01-05